Levopropoxyphene Napsylate

CHEMBL1593906 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
565.7 g/mol
LogP
Phase
4

A napsylate form of levopropoxyphene with the same therapeutic properties. A non-opioid cough suppressant withdrawn from many markets due to cardiac safety concerns.

分子量

565.7000 g/mol

TPSA

93.30 Ų

治疗领域

作用机制

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC(=O)O[C@@](Cc1ccccc1)(c1ccccc1)[C@@H](C)CN(C)C.O=S(=O)(O)c1ccc2ccccc2c1

InChI

InChI=1S/C22H29NO2.C10H8O3S/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10/h6-15,18H,5,16-17H2,1-4H3;1-7H,(H,11,12,13)/t18-,22+;/m0./s1

Molecular Formula

C32H39NO6S

HBD / HBA

2 / 7

可旋转键数

10

重原子数

40

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A napsylate form of levopropoxyphene with the same therapeutic properties. A non-opioid cough suppressant withdrawn from many markets due to cardiac safety concerns.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Levopropoxyphene Napsylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1593906. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 16051927. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.